Aspirin and NSAIDs as Cancer Preventive Agents: A Review
Nadin Bedikyan1, Oytun Erbaş1
1ERBAS Institute of Experimental Medicine, Illinois, USA & Gebze, Türkiye
Keywords: Aspirin, cancer, COX gene, inflammation, NSAIDs.
Abstract
Aspirin and non-steroidal anti-inflammatory drugs are widely utilized pharmaceuticals globally for their analgesic, anti-inflammatory, and antipyretic properties. These compounds are known to inhibit the enzyme cyclooxygenase, whose upregulation is implicated in various cancers, thereby suppressing the synthesis of prostaglandin, prostacyclin, and thromboxane in cancer cell lines, thereby manifesting anticancer attributes. This review aims to investigate the potential utility of aspirin as a neoadjuvant in several cancer types, particularly colorectal cancer, based on its anticancer efficacy, elucidate its mechanistic roles across diverse cancer types, and ascertain whether the risk of cancer escalation or mitigation varies depending on drug dosages across different cancer entities.
Cite this article as: Bedikyan N, Erbaş O. Aspirin and NSAIDs as Cancer Preventive Agents: A Review. JEB Med Sci 2024;5(2):205-209.
The authors declared no conflicts of interest with respect to the authorship and/or publication of this article.
The authors received no financial support for the research and/or authorship of this article.